Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 5/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 5/20 | 0.50 |
| ▸ | RELA | Q04206 | 5/20 | 0.50 |
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 2/20 | 0.42 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2936974 | 0.79 | GAA (0.53) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL3307631 | 0.79 | GAA (0.53) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL9846492 | 0.79 | GAA (0.53) | GAANFKB1NFKB2RELABTK | |
| Nonane SCHEMBL28141454 | 0.77 | GAA (0.39) | GAANFKB1NFKB2RELA | |
| SCHEMBL570801 | 0.77 | GAA (0.54) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL8700402 | 0.77 | GAA (0.50) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL14153070 | 0.77 | GAA (0.50) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL15502088 | 0.76 | GAA (0.54) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL18570971 | 0.76 | GAA (0.54) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL8225701 | 0.76 | GAA (0.54) | GAANFKB1NFKB2RELABTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1921062-A2 | Amino acid derivatives as HIV aspartyl protease inhibitors | Ambrilia Biopharma Inc. (CA) | 2008-05-14 | — | — | EP | disclosed |
| EP-1458378-B1 | AMINO ACID DERIVATIVES USEFUL FOR THE TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARM INC (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20060079550-A1 | Amino acid derivatives useful for the treatment of alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2006-04-13 | — | — | US | disclosed |
| EP-1263716-A2 | AMINO ACID DERIVATIVES AS HIV ASPARTYL PROTEASE INHIBITORS | Pharmacor Inc. (CA) | 2002-12-11 | — | — | EP | disclosed |
| US-6455587-B1 | AROMATIC SULFONYL DERIVATIVES | PHARMACOR INC. (CA) | 2002-09-24 | — | — | US | disclosed |
| WO-2001068593-A2 | AMINO ACID DERIVATIVES AS HIV ASPARTYL PROTEASE INHIBITORS | PHARMACOR INC. (CA) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079550-A1 | Amino acid derivatives useful for the treatment of alzheimer's disease | BACE1, APP, PSEN1 | GAA 197/4885NFKB1 1593/4885NFKB2 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.